Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

BMY

Bristol-Myers

NYSE

Real-time Quotes | Nasdaq Last Sale

60.45

+0.02

+0.03%

After Hours: 60.54 +0.09 +0.15% 19:35 03/08 EST

OPEN

60.60

PREV CLOSE

60.43

HIGH

61.72

LOW

60.13

VOLUME

10.62M

TURNOVER

52 WEEK HIGH

67.16

52 WEEK LOW

45.76

MARKET CAP

135.44B

P/E (TTM)

-15.0530

Global Byler Disease Market Things to Focus on to Ensure Long-term Success | AstraZeneca PLC, Pfizer Inc, Bristol-Myers Squibb Company, Gilead Science Inc., Johnson & Johnson Private Limited.

Mar 08, 2021 (MARKITWIRED via COMTEX) -- VALLEY COTTAGE, N.Y. -Impact of COVID-19 on the Healthcare Industry The COVID-19 pandemic has causedsevere impacts...

Markitwired · 4h ago

Roche (RHHBY) Withdraws Bladder Cancer Indication for Tecentriq

Zacks.com · 5h ago

ICOS-Next Generation Immunotherapy Competitive Landscape and Market Forecast – 2035

ABNewswire · 6h ago

Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL

Zacks.com · 6h ago

NIH starts trial enrollment for Bristol/Pfizer's Eliquis for blood clots in COVID patients

The National Institutes of Health (NIH) has begun enrollment in the third and final phase 3 trial evaluating the effectiveness of Bristol Myers Squibb (BMY) and Pfizer's (PFE) blood thinner

Seekingalpha · 7h ago

Atrial Fibrillation Surgery Devices Market Share, Development by Companies Outlook, Growth Prospects and Key Opportunities by 2030

Heraldkeepers · 9h ago

Autoimmune Diseases Treatment Market Research Report 2021 Elaborate Analysis With Growth Forecast To 2028

Heraldkeepers · 9h ago

Bile Duct Cancer Market Share, Size, Trends, Industry Analysis to 2027 by Disease Type; By Technology; By Specialty; By End-Use; By Regions

Mar 08, 2021 (Heraldkeepers) -- The Global Bile Duct Cancer Market share is segmented on the lines of its technology, treatment, application and regional....

Heraldkeepers · 9h ago

Forecast

Actual (USD)

Estimate (USD)

Income StatementMore

Net Income (USD)

YoY (%)

Balance SheetMore

Total Assets (USD)

Total Liabilities (USD)

Debt to Asset (%)

Cash FlowMore

Operating (USD)

YoY (%)

Learn about the latest financial forecast of BMY. Analyze the recent business situations of Bristol-Myers through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BMY stock price target is 75.53 with a high estimate of 86.00 and a low estimate of 66.00.

EPS

Institutional Holdings

Institutions: 2.98K

Institutional Holdings: 1.74B

% Owned: 77.45%

Shares Outstanding: 2.24B

TypeInstitutionsShares

Increased

922

75.49M

New

348

6.96M

Decreased

852

90.97M

Sold Out

Performance
Asset Allocation
Dividend History

No Data

Industry

Pharmaceuticals

+0.16%

Pharmaceuticals & Medical Research

-0.50%

Key Executives

Chairman/Chief Executive Officer/Director

Giovanni Caforio

Chief Financial Officer/Executive Vice President

David Elkins

Chief Human Resource Officer/Senior Vice President

Ann Judge

Chief Human Resource Officer/Senior Vice President

Ann Powell

Executive Vice President/General Counsel

Sandra Leung

Executive Vice President/Director of Investor Relations

John Elicker

Executive Vice President

Nadim Ahmed

Executive Vice President

Christopher Boerner

Executive Vice President

Samit Hirawat

Executive Vice President

Kathryn Metcalfe

Executive Vice President

Elizabeth Mily

Executive Vice President

Louis Schmukler

Executive Vice President

Rupert Vessey

Senior Vice President/Chief Information Officer

Paul von Autenried

Senior Vice President/Chief Compliance Officer

Adam Dubow

Senior Vice President/Controller

Karen Santiago

Senior Vice President

Joseph Eid

Vice President/Director of Investor Relations/IR Contact Officer

Tim Power

Lead Director/Independent Director

Vicki Sato

Lead Director/Independent Director

vicki Sato

Independent Director

Peter Arduini

Independent Director

Robert Bertolini

Independent Director

Michael Bonney

Independent Director

Matthew Emmens

Independent Director

Julia Haller

Independent Director

Dinesh Paliwal

Independent Director

Paula Price

Independent Director

Derica Rice

Independent Director

Theodore Samuels

Independent Director

Gerald Storch

Independent Director

Karen Vousden

Independent Director

Phyllis Yale

Declaration Date Dividend Per Share Ex-Div Date: 03/01/2021
Dividend USD 0.49
03/31/2021; 12/10/2020
Dividend USD 0.49
12/31/2020; 09/10/2020
Dividend USD 0.45
10/01/2020; 06/11/2020
Dividend USD 0.45
07/02/2020; 03/02/2020
Dividend USD 0.45
04/02/2020; 12/05/2019
Dividend USD 0.45
01/02/2020; 09/11/2019
Dividend USD 0.41
10/03/2019; 06/13/2019
Dividend USD 0.41
07/03/2019; 03/07/2019
Dividend USD 0.41
04/04/2019; 12/06/2018
Dividend USD 0.41
01/03/2019; 09/12/2018
Dividend USD 0.4
10/04/2018; 06/14/2018
Dividend USD 0.4
07/05/2018; 03/01/2018
Dividend USD 0.4
04/05/2018; 12/07/2017
Dividend USD 0.4
01/04/2018; 09/13/2017
Dividend USD 0.39
10/05/2017; 06/14/2017
Dividend USD 0.39
07/05/2017; 03/03/2017
Dividend USD 0.39
04/05/2017; 12/09/2016
Dividend USD 0.39
01/04/2017; 08/04/2016
Dividend USD 0.38
10/05/2016; 06/13/2016
Dividend USD 0.38
06/29/2016; 03/04/2016
Dividend USD 0.38
03/30/2016; 12/10/2015
Dividend USD 0.38
12/30/2015; 09/18/2015
Dividend USD 0.37
09/30/2015; 06/19/2015
Dividend USD 0.37
07/01/2015; 03/05/2015
Dividend USD 0.37
04/01/2015; 12/10/2014
Dividend USD 0.37
12/30/2014; 09/17/2014
Dividend USD 0.36
10/01/2014; 06/18/2014
Dividend USD 0.36
07/01/2014; 03/04/2014
Dividend USD 0.36
04/02/2014; 12/19/2013
Dividend USD 0.36
12/31/2013; 09/18/2013
Dividend USD 0.35
10/02/2013; 06/20/2013
Dividend USD 0.35
07/02/2013

All
Financials
Insiders

About BMY

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

Webull offers kinds of Bristol-Myers Squibb Co stock information, including NYSE:BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.